Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 inhibitor plus decitabine versus decitabine alone in high-risk refractory myeloid malignancies
ChiCTR1900025020Phase 4Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of decitabine in myeloid diseases (2 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoints: Overall response rate, Complete response and 2 more. Started Aug 2019; status: recruiting.
02
Drugs
decitabine
03
Conditions
myeloid diseases
Beyond the preview
Go deeper on ChiCTR1900025020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025020.